Professor Susan Short of the University of Leeds School of Medicine is running a 3-year clinical trial to provide new insights on the treatment of the most aggressive form of brain tumour, Glioblastoma. The trial, named ARISTOCRAT, utilises cannabinoids in Glioblastoma treatment. In this article we explore the trials aims and it’s implications for the community.
About the trial
The ARISTOCRAT trial is exploring the use of a specific Cannabis extract called Nabiximols (trade name, Sativex) in Glioblastoma treatment. The research is exploring whether Nabiximols extends the lives of those with Glioblastoma when combined with the standard chemotherapy treatment. Nabiximols has been used to successfully treat other conditions such as multiple sclerosis.
In 2021, the phase I ARISTOCRAT trial determined the safety of this treatment in conjunction with chemotherapy. The trial found the treatment was well tolerated in the 27 patient cohort.
The primary outcome of the phase II trial focuses on extending overall survival. Unfortunately this is expected to be only 10 months when in standard care. Secondary outcomes involve monitoring progression-free survival time, quality of life and learning of any adverse effects.
What does this mean for the Glioblastoma community?
The trial is recruiting over 230 Glioblastoma patients from across the UK to take part in the trial. This will allow for many to have the chance for improved outcomes and the potential for a new addition or alternative to standard care.
Furthermore, the trial has the potential to influence new bold and forward-thinking research in the clinical space. As a result, Glioblastoma patients and their loved ones could benefit from a healthier and more beneficial landscape after their diagnosis.
How do I find out more?
- To read more about the trial, visit the ARISTOCRAT webpage, here.
- You can find the trial on the ISRCTN record here.
- For further details, you can read about the trial and it’s recruitment on Cancer Research UK website, here.
- Find out more about the patients involved in the trial and what it means to them in this University of Leeds article, here.
Want to receive all the latest research straight to your inbox?
Sign-up our curated, jargon-free weekly research newsletter. Click here to fill out our contact form and select ‘research’ to opt into our research newsletter.
Get involved with research…
If you would like to use your experience and insight to support clinical research, consider signing up to be a PRIME advocate for brainstrust.
If you or someone you love is living with a brain tumour and have any questions around this latest news, or want to access support, give us a call on 01983 292 405 or email email@example.com. You can also visit our little brainstrust website which features support for children affected by brain tumour.